Compare Jones Lang LaSalle Inc (JLL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Recursion Pharmaceuticals Inc — how do they compare? Jones Lang LaSalle Inc trades at $303.6 (market cap $13.65B), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.31B). The key difference: Jones Lang LaSalle Inc is far larger — about 5.9× Recursion Pharmaceuticals Inc's market cap, and Jones Lang LaSalle Inc is more actively traded (465,758 versus 40,478,768). Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JLL | RXRX | |
|---|---|---|
Market Cap | $13.65B | $2.31B |
Volume | 465,758 | 40,478,768 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $6.79 |
52-Week Low | $280.16 | $2.84 |
Typical Hold Time | 71 Days | 22 Days |
Enterprise Value | $16.41B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% today, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $5.26 beating expectations by 15%. Revenue growth accelerated to $26.12 billion in 2025, while net income margin improved to 3.64%. Recent acquisitions and financing deals demonstrate continued expansion in key markets.
The stock presents a compelling value opportunity with a P/E of 14.23 and P/S of 0.52 below industry averages. Analyst consensus targets $450.50, implying 52% upside potential. Key risks include real estate market cyclicality and execution challenges in global expansion. Strong cash flow generation and institutional buying support the bullish fundamental case despite near-term technical weakness.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
